PRECLINICAL DEVELOPMENT OF MONOCLONAL ANTIBODIES AND RELATED BIOLOGICALS: EMERGING TECHNOLOGIES AND NEW THERAPEUTIC CANDIDATES
Monoclonal antibodies form a fastest flourishing shred of a curative industry, with sum annual sales approaching to tip billion in a subsequent 4 years. twenty-three full-size monoclonal antibodies as good as 3 monoclonal antibody fragments have been launched so far, multiform carrying fast reached ‘blockbuster status’ (annual sales of over billion). Between 1995 as good as 2007, a series of monoclonal antibody-based drug possibilities entering clinical trials some-more than tripled, as good as this enlargement is continuing.
This inform explains what monoclonal antibodies are, as good as because vast curative companies have been investing so heavily both in building such drug internally as good as appropriation monoclonal antibody possibilities from others. More than 80 renouned as good as rising technologies have been named, explained as good as with pictures with strange full-color diagrams.
The newest call of drug possibilities formed upon these technologies can be seen in some-more than 200 box studies, that brand each blurb association good known to have carried out preclinical studies of healing monoclonal antibodies in a final year. Finally, prospects as good as hurdles for a destiny of this margin have been discussed, with opinions from systematic pioneers as good as attention leaders.
Key facilities of this report
• Illustrated ‘beginners guide’ to monoclonal antibodies: What they are, how they have been done as good as because they reason such good guarantee for a diagnosis of disease.
• More than 80 descriptions of exclusive technologies right away in make make use of of around a universe to name furnish as good as re-engineer monoclonal antibodies.
• More than thirty original, full-color diagrams illustrating a scholarship as good as record of monoclonal antibodies, both as they crop up in inlet as good as in a innumerable brand brand brand brand brand brand brand new forms right away being assessed in preclinical trials.
Scope of this report
• Understand a simple qualities of monoclonal antibodies as good as how these qualities interpret in to singular healing as good as blurb facilities for drug candidates.
• Appreciate a hurdles as good as risks of monoclonal antibodies, as good as their promise.
• Assess earnest brand brand brand brand brand brand brand new technologies for investment or in-licensing.
• Identify that companies have been concerned in this field, as good as what they have been doing.
• Predict a kinds of drug that will come in clinical trials in a subsequent 1-4 years as good as might strech a marketplace in a subsequent 5-10 years.
Key Market Issues
• New monoclonal antibodies can be used to aim brand brand brand brand brand brand brand new mildew processes that have been not right away addressed by any alternative therapies, thereby accessing marketplace areas with tall unmet demand.
• The elemental specificity as good as predictability of monoclonal antibodies have been shown to digest drug growth times as good as enlarge rates of success in preclinical as good as clinical trials, relations to non-biological ‘small molecule’ drugs.
• High barriers to entrance right away forestall most brand brand brand brand brand brand brand new companies from entering this field. The techniques right away used to create, name as good as cgange monoclonal antibodies for tellurian healing make make use of of have been stable by egghead property, that a originators urge vigorously. However, multiform early patents upon elemental techniques will end really soon.
Key commentary from this report
• Early hurdles relating to immunogenicity, hankie penetration, administration department as good as prolongation of monoclonal antibodies have been being addressed by innumerable brand brand brand brand brand brand brand new technologies.
• The rival benefits of identifying as good as addressing brand brand brand brand brand brand brand new healing targets go upon to yield incentives for brand brand brand brand brand brand brand new aim preference as good as monoclonal antibody marker programs.
• Established techniques for ‘humanization’ of non-human monoclonal antibodies sojourn popular, notwithstanding a climb of newer ‘fully human’ monoclonal antibody technologies. This might be due to a strong inlet of a progressing technologies and/or a approaching expiries of pass patents.
• Genetic engineering methods as good as novel ‘host cell’ prolongation systems have been being used to optimize as good as cgange functions of monoclonal antibodies. Proprietary platforms regulating these methods have been during large protected to most of a vital players in a biopharmaceutical industry.
Key questions answered
• What have been monoclonal antibodies, as good as what can they do?
• Why have been so most companies building them as healing agents?
• Which companies have been right away operative to countenance as good as rise a ultimate era of drug possibilities formed upon monoclonal antibodies?
• What technological as good as regulatory hurdles face these companies in building such possibilities as good as bringing drug to market?
Table of Content:
Executive outline 16
An key to monoclonal antibodies 16
Identifying non-human monoclonal antibodies 17
Optimizing full-length antibodies 17
Fully tellurian monoclonal antibodies 18
Antibody conjugates 19
Novel contracting molecules subsequent from antibodies 20
Chapter 1 An key to monoclonal antibodies 22
Summary 22
Introduction 23
Antibodies in inlet 23
Advantages of monoclonal antibodies as drug 29
Target operation 29
Predictability 30
Pharmacokinetics 30
Technology insurance 30
Challenges as good as opportunities for a subsequent era of monoclonal antibodies 31
Target preference 31
Species specificity 33
Pharmacokinetics 34
Manufacture 34
Monoclonal antibody drug already during marketplace 35
Orthoclone OKT3 35
Remicade 36
Rituxan 36
Zenapax 37
Synagis 37
Humira 37
Vectibix 38
Simponi 38
Lucentis 38
Cimzia 39
Tysabri 39
Preclinical growth of healing drug 40
Proof of judgment 40
Safety form 40
Conclusions 42
Chapter 2 Identifying non-human monoclonal antibodies 46
Summary 46
Introduction 47
Technology platforms 47
Hybridoma record 48
RabMAbs 48
SLAM 48
Human Response Platform 49
DIAAD 49
ImmuneY2 50
iMAB 50
Fusion Expression Technology 51
ProMIS 51
AbScreen 51
AbProt 52
BioArctic height 52
FunctionFIRST 52
Case studies 52
Abbott Labs 53
AbGenomics 53
Alethia 53
Amorfix 53
Arrowsmith Technologies 54
AVEO 55
BioSceptre 55
Canadian Bio Med Systems 55
Cangene 56
CellAct 56
CoGenesys 57
Crucell 57
CSL 58
Daewoong 58
DKFZ 58
Epitomics 59
Fusion Antibodies 59
Ganymed Pharmaceuticals 60
GeNeuro 60
Genitope 60
GSK 61
Heat Biologics 61
Immuno-Biological Labs 61
ImmunoGen 62
Immutep 62
InflaRx 63
Innate Pharma 63
Inotek 63
Intercell 64
LigoCyte 64
MedImmune 64
Morphotek 65
NeoGenix 65
Northwest Biotherapeutics 66
Novartis 66
Novo Nordisk 67
OncoMed 67
Perseis Therapeutics 67
Pfizer 68
Pharma Research Toronto 69
Prana Biotech 69
Quest PharmaTech 69
Recepta Biopharma 69
Receptor-Logic 70
Roche 70
Shanghai CP Guojian 71
Suzhou Stainwei Biotech 71
Therapure 71
ThromboGenics 71
Thrombotargets 72
Tolerx 72
Trillium 73
Vaccinex 73
Wilex 73
ZymoGenetics 74
Conclusions 81
Chapter 3 Optimizing full-length antibodies 84
Summary 84
Introduction 85
Technology platforms 86
Chimeric antibodies 86
CDR grafting 88
SMART 90
Superhumanisation 90
Framework Patching 91
Composite Human Antibody 91
ATLAb 92
Humaneering 92
MLG 93
DeImmunisation 93
Humanation 93
Human Engineering 94
FcX 94
The LEX System 94
Potelligent 94
Complegent 95
BestMAb 97
ImmunoBody 97
EB66 97
Synageva Expression Platform 98
XmAb 98
Sugar Engineered Antibodies 99
Wox 99
Case studies 101
Abbott Labs 101
Advanced Immune Therapeutics 102
Alder Biopharm 102
Alethia 103
Alexion 103
Antisoma 103
Arana 104
Attenuon 105
AVEO 106
BioArctic Neuroscience 106
Biogen Idec 106
Biolex 107
BioXell 108
China Synthetic Rubber Corp 108
CSL 108
CureTech 109
Direvo 109
DSX 109
Eli Lilly 110
Epitomics 110
Faron Pharm 110
Femta Pharm 110
Forerunner Pharma Research 111
Fusion Antibodies 111
Galaxy Biotech 112
Galileo Oncologics 112
Genentech 113
Glenmark 113
GlycoForm 114
Glycotope 114
ImmunoCellular Therapeutics 114
Immunomedics 115
Innate Pharma 115
InNexus Biotech 115
Intellect Neurosciences 116
Isu Abxis 116
Janssen Alzheimer Immunotherapy 116
KaloBios 117
Keel Pharm 117
LigoCyte 117
Lpath 117
Mabion 118
MacroGenics 118
MaimoniDex 119
MAT Biopharma 119
MedImmune 119
Medtronic 120
Micromet 120
NKT Therapeutics 120
Opsona 121
Percipio 121
Pharma Research Toronto 122
ProtAb 122
Scancell 123
Selexys 123
SinoMab Bioscience 124
Synageva 124
TaiMed 124
Trillium 125
United Biomedical 125
Vascular Pharm 125
VasGene 126
Vegenics 126
Vybion 126
Xencor 127
Conclusions
Read Also
Pages: 1 2
Tags: Antibodies, Biologicals, Candidates, Development, Emerging, Monoclonal, Preclinical, Related, technologies, Therapeutic